Quarterly Financial Report: U.S. Corporations: Pharmaceuticals and Medicines: All Other Nonoperating Income (Expense)
QFRD110385USNO • Economic Data from Federal Reserve Economic Data (FRED)
Latest Value
10,175.00
Year-over-Year Change
59.26%
Date Range
10/1/2000 - 4/1/2025
Summary
Tracks nonoperating income and expenses for U.S. pharmaceutical corporations. Provides insight into financial performance beyond core business operations.
Analysis & Context
This economic indicator provides valuable insights into current market conditions and economic trends. The data is updated regularly by the Federal Reserve and represents one of the most reliable sources for economic analysis.
Understanding this metric helps economists, policymakers, and investors make informed decisions about economic conditions and future trends. The interactive chart above allows you to explore historical patterns and identify key trends over time.
About This Dataset
This metric captures additional financial activities outside primary pharmaceutical business revenue. It helps analysts understand comprehensive corporate financial health.
Methodology
Collected quarterly through comprehensive corporate financial reporting surveys.
Historical Context
Used by investors and financial analysts to assess pharmaceutical company financial strategies.
Key Facts
- Quarterly reporting metric for pharmaceutical corporations
- Includes income from investments and non-core activities
- Critical for comprehensive financial analysis
FAQs
Q: What does nonoperating income mean for pharmaceutical companies?
A: Represents financial gains outside core business operations. Includes investments, asset sales, and other peripheral income sources.
Q: How often is this financial data updated?
A: Reported quarterly by the U.S. Federal Reserve. Provides current snapshot of pharmaceutical corporate finances.
Q: Why do investors care about nonoperating income?
A: Reveals additional revenue streams and financial management strategies beyond primary business activities.
Q: How does this metric differ from operating income?
A: Captures financial activities not directly related to primary pharmaceutical business operations.
Q: Are there limitations to this financial reporting?
A: Represents a snapshot in time and should be analyzed alongside other financial indicators.
Related Trends
Quarterly Financial Report: U.S. Corporations: All Nondurable Manufacturing: Cash and Demand Deposits in the U.S.
QFR201NDUUSNO
Quarterly Financial Report: U.S. Corporations: Foundries: Cash Dividends Charged to Retained Earnings This Quarter
QFR120331USNO
Quarterly Financial Report: U.S. Corporations: Wholesale Trade, Nondurable Goods: Time Deposits in the U.S., Including Negotiable Certificates of Deposit
QFR202422USNO
Quarterly Financial Report: U.S. Corporations: Transportation Equipment: Current Portion of Long-Term Debt, Due in 1 Year or Less: Loans from Banks
QFR310TRAUSNO
Quarterly Financial Report: U.S. Corporations: All Other Information: Cash Dividends Charged to Retained Earnings This Quarter
QFR120519USNO
Quarterly Financial Report: U.S. Corporations: Communications Equipment: Net Working Capital
QFRNWC384USNO
Citation
U.S. Federal Reserve, Quarterly Financial Report: Pharmaceuticals and Medicines Nonoperating Income (QFRD110385USNO), retrieved from FRED.